Priaxon, a privately held pharmaceutical company developing small molecules for the modulation of protein-protein interactions, has appointed Constance Hoefer as Chief Development Officer (CDO). She will oversee non-clinical and early clinical development at the German company.
Hoefer has more than 20 years of international non-clinical development and management experience in academic and regulatory areas as well as holding industry roles in pharmaceutical and biotech companies.
She began her industry career with Celltech, followed by increasingly responsible roles with Solvay Pharmaceuticals and Merck KGaA, before establishing an independent consultancy in 2006.
Since then, she has contributed her knowledge and experience to government institution spin-outs as well as national and international pharma clients. Most recently, she was Vice President and Head of Non-Clinical Development at Medigene.
